APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for the Treatment of Refractory Gout

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025195 pages

Choose your research edition.

Industry ResearchDrugs for the Treatment of Refractory Gout Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for the Treatment of Refractory Gout Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Drugs for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for the Treatment of Refractory Gout market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for the Treatment of Refractory Gout include Zhuhai Livzon Biotechnology, Sobi, Qilu Pharmaceutical, Roche, Bio-Thera Solutions, Sandoz, Pfizer, Novartis and Kiniksa Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for the Treatment of Refractory Gout market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for the Treatment of Refractory Gout and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for the Treatment of Refractory Gout sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for the Treatment of Refractory Gout market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for the Treatment of Refractory Gout Segment by Company

Zhuhai Livzon Biotechnology

Sobi

Qilu Pharmaceutical

Roche

Bio-Thera Solutions

Sandoz

Pfizer

Novartis

Kiniksa Pharmaceuticals

Horizo​​n Therapeutics

Hanwha Chemical

Fresenius Kabi

Biogen

Amgen

Drugs for the Treatment of Refractory Gout Segment by Type

Tumor Necrosis Factor Inhibitors

PEGylated Recombinant Uricase

Interleukin Inhibitors

Other

Drugs for the Treatment of Refractory Gout Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Drugs for the Treatment of Refractory Gout Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for the Treatment of Refractory Gout market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for the Treatment of Refractory Gout and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for the Treatment of Refractory Gout.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for the Treatment of Refractory Gout market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for the Treatment of Refractory Gout in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for the Treatment of Refractory Gout in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for the Treatment of Refractory Gout Industry Trends Table 2. Drugs for the Treatment of Refractory Gout Industry Drivers Table 3. Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges Table 4. Drugs for the Treatment of Refractory Gout Industry Restraints Table 5. Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for the Treatment of Refractory Gout Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Manufacturers Table 9. Global Drugs for the Treatment of Refractory Gout Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs for the Treatment of Refractory Gout Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for the Treatment of Refractory Gout Manufacturers, Product Type & Application Table 13. Global Drugs for the Treatment of Refractory Gout Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for the Treatment of Refractory Gout by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tumor Necrosis Factor Inhibitors Table 17. Major Manufacturers of PEGylated Recombinant Uricase Table 18. Major Manufacturers of Interleukin Inhibitors Table 19. Major Manufacturers of Other Table 20. Global Drugs for the Treatment of Refractory Gout Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 22. Global Drugs for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 23. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2026) Table 24. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2027-2032) Table 25. Global Drugs for the Treatment of Refractory Gout Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (K Units) Table 27. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (K Units) Table 28. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2026) Table 29. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital and Clinic Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Other Table 33. Global Drugs for the Treatment of Refractory Gout Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 35. Global Drugs for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 36. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2026) Table 37. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2027-2032) Table 38. Global Drugs for the Treatment of Refractory Gout Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (K Units) Table 40. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (K Units) Table 41. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2026) Table 42. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2027-2032) Table 43. Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026) & (K Units) Table 45. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2026) Table 46. Global Drugs for the Treatment of Refractory Gout Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Drugs for the Treatment of Refractory Gout Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 50. North America Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 51. Europe Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 53. Europe Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 60. Global Drugs for the Treatment of Refractory Gout Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Drugs for the Treatment of Refractory Gout Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2026) Table 64. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2027-2032) Table 65. Zhuhai Livzon Biotechnology Company Information Table 66. Zhuhai Livzon Biotechnology Business Overview Table 67. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio Table 69. Zhuhai Livzon Biotechnology Recent Development Table 70. Sobi Company Information Table 71. Sobi Business Overview Table 72. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sobi Drugs for the Treatment of Refractory Gout Product Portfolio Table 74. Sobi Recent Development Table 75. Qilu Pharmaceutical Company Information Table 76. Qilu Pharmaceutical Business Overview Table 77. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio Table 79. Qilu Pharmaceutical Recent Development Table 80. Roche Company Information Table 81. Roche Business Overview Table 82. Roche Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Roche Drugs for the Treatment of Refractory Gout Product Portfolio Table 84. Roche Recent Development Table 85. Bio-Thera Solutions Company Information Table 86. Bio-Thera Solutions Business Overview Table 87. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio Table 89. Bio-Thera Solutions Recent Development Table 90. Sandoz Company Information Table 91. Sandoz Business Overview Table 92. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio Table 94. Sandoz Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio Table 99. Pfizer Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Novartis Drugs for the Treatment of Refractory Gout Product Portfolio Table 104. Novartis Recent Development Table 105. Kiniksa Pharmaceuticals Company Information Table 106. Kiniksa Pharmaceuticals Business Overview Table 107. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio Table 109. Kiniksa Pharmaceuticals Recent Development Table 110. Horizo​​n Therapeutics Company Information Table 111. Horizo​​n Therapeutics Business Overview Table 112. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio Table 114. Horizo​​n Therapeutics Recent Development Table 115. Hanwha Chemical Company Information Table 116. Hanwha Chemical Business Overview Table 117. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio Table 119. Hanwha Chemical Recent Development Table 120. Fresenius Kabi Company Information Table 121. Fresenius Kabi Business Overview Table 122. Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio Table 124. Fresenius Kabi Recent Development Table 125. Biogen Company Information Table 126. Biogen Business Overview Table 127. Biogen Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Biogen Drugs for the Treatment of Refractory Gout Product Portfolio Table 129. Biogen Recent Development Table 130. Amgen Company Information Table 131. Amgen Business Overview Table 132. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Amgen Drugs for the Treatment of Refractory Gout Product Portfolio Table 134. Amgen Recent Development Table 135. Key Raw Materials Table 136. Raw Materials Key Suppliers Table 137. Drugs for the Treatment of Refractory Gout Distributors List Table 138. Drugs for the Treatment of Refractory Gout Customers List Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Drugs for the Treatment of Refractory Gout Product Image Figure 2. Global Drugs for the Treatment of Refractory Gout Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for the Treatment of Refractory Gout Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for the Treatment of Refractory Gout Sales (2021-2032) & (K Units) Figure 5. Global Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for the Treatment of Refractory Gout Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tumor Necrosis Factor Inhibitors Image Figure 9. PEGylated Recombinant Uricase Image Figure 10. Interleukin Inhibitors Image Figure 11. Other Image Figure 12. Global Drugs for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Drugs for the Treatment of Refractory Gout Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032) Figure 15. Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Drugs for the Treatment of Refractory Gout Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032) Figure 18. Hospital and Clinic Image Figure 19. Retail Pharmacies Image Figure 20. Other Image Figure 21. Global Drugs for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Drugs for the Treatment of Refractory Gout Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032) Figure 24. Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Drugs for the Treatment of Refractory Gout Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032) Figure 27. North America Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 29. U.S. Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 34. Germany Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 41. China Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 49. Brazil Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Drugs for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Drugs for the Treatment of Refractory Gout Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 60. North America Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 62. Europe Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Drugs for the Treatment of Refractory Gout Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Drugs for the Treatment of Refractory Gout Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Tumor Necrosis Factor Inhibitors
  • PEGylated Recombinant Uricase
  • Interleukin Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Zhuhai Livzon Biotechnology
  • Sobi
  • Qilu Pharmaceutical
  • Roche
  • Bio-Thera Solutions
  • Sandoz
  • Pfizer
  • Novartis
  • Kiniksa Pharmaceuticals
  • Horizo​​n Therapeutics
  • Hanwha Chemical
  • Fresenius Kabi
  • Biogen
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for the Treatment of Refractory Gout Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for the Treatment of Refractory Gout Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for the Treatment of Refractory Gout Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for the Treatment of Refractory Gout Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for the Treatment of Refractory Gout Market Dynamics
  1. 2.1 Drugs for the Treatment of Refractory Gout Industry Trends
  2. 2.2 Drugs for the Treatment of Refractory Gout Industry Drivers
  3. 2.3 Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges
  4. 2.4 Drugs for the Treatment of Refractory Gout Industry Restraints
3 Drugs for the Treatment of Refractory Gout Market by Manufacturers
  1. 3.1 Global Drugs for the Treatment of Refractory Gout Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for the Treatment of Refractory Gout Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for the Treatment of Refractory Gout Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for the Treatment of Refractory Gout Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for the Treatment of Refractory Gout Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for the Treatment of Refractory Gout Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for the Treatment of Refractory Gout Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for the Treatment of Refractory Gout Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for the Treatment of Refractory Gout Tier 1, Tier 2, and Tier 3
4 Drugs for the Treatment of Refractory Gout Market by Type
  1. 4.1 Drugs for the Treatment of Refractory Gout Type Introduction
  2. 4.1.1 Tumor Necrosis Factor Inhibitors
  3. 4.1.2 PEGylated Recombinant Uricase
  4. 4.1.3 Interleukin Inhibitors
  5. 4.1.4 Other
  6. 4.2 Global Drugs for the Treatment of Refractory Gout Sales by Type
  7. 4.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Type (2021-2032)
  9. 4.2.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032)
  10. 4.3 Global Drugs for the Treatment of Refractory Gout Revenue by Type
  11. 4.3.1 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  13. 4.3.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032)
5 Drugs for the Treatment of Refractory Gout Market by Application
  1. 5.1 Drugs for the Treatment of Refractory Gout Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Drugs for the Treatment of Refractory Gout Sales by Application
  6. 5.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 5.2.3 Global Drugs for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032)
  9. 5.3 Global Drugs for the Treatment of Refractory Gout Revenue by Application
  10. 5.3.1 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  12. 5.3.3 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032)
6 Global Drugs for the Treatment of Refractory Gout Sales by Region
  1. 6.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for the Treatment of Refractory Gout Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for the Treatment of Refractory Gout Revenue by Region
  1. 7.1 Global Drugs for the Treatment of Refractory Gout Revenue by Region
  2. 7.1.1 Global Drugs for the Treatment of Refractory Gout Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for the Treatment of Refractory Gout Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for the Treatment of Refractory Gout Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for the Treatment of Refractory Gout Revenue (2021-2032)
  8. 7.2.2 North America Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for the Treatment of Refractory Gout Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for the Treatment of Refractory Gout Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai Livzon Biotechnology
  2. 8.1.1 Zhuhai Livzon Biotechnology Company Information
  3. 8.1.2 Zhuhai Livzon Biotechnology Business Overview
  4. 8.1.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio
  6. 8.1.5 Zhuhai Livzon Biotechnology Recent Developments
  7. 8.2 Sobi
  8. 8.2.1 Sobi Company Information
  9. 8.2.2 Sobi Business Overview
  10. 8.2.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sobi Drugs for the Treatment of Refractory Gout Product Portfolio
  12. 8.2.5 Sobi Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Drugs for the Treatment of Refractory Gout Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Bio-Thera Solutions
  26. 8.5.1 Bio-Thera Solutions Company Information
  27. 8.5.2 Bio-Thera Solutions Business Overview
  28. 8.5.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio
  30. 8.5.5 Bio-Thera Solutions Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Drugs for the Treatment of Refractory Gout Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Kiniksa Pharmaceuticals
  50. 8.9.1 Kiniksa Pharmaceuticals Company Information
  51. 8.9.2 Kiniksa Pharmaceuticals Business Overview
  52. 8.9.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio
  54. 8.9.5 Kiniksa Pharmaceuticals Recent Developments
  55. 8.10 Horizo​​n Therapeutics
  56. 8.10.1 Horizo​​n Therapeutics Company Information
  57. 8.10.2 Horizo​​n Therapeutics Business Overview
  58. 8.10.3 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio
  60. 8.10.5 Horizo​​n Therapeutics Recent Developments
  61. 8.11 Hanwha Chemical
  62. 8.11.1 Hanwha Chemical Company Information
  63. 8.11.2 Hanwha Chemical Business Overview
  64. 8.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio
  66. 8.11.5 Hanwha Chemical Recent Developments
  67. 8.12 Fresenius Kabi
  68. 8.12.1 Fresenius Kabi Company Information
  69. 8.12.2 Fresenius Kabi Business Overview
  70. 8.12.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio
  72. 8.12.5 Fresenius Kabi Recent Developments
  73. 8.13 Biogen
  74. 8.13.1 Biogen Company Information
  75. 8.13.2 Biogen Business Overview
  76. 8.13.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biogen Drugs for the Treatment of Refractory Gout Product Portfolio
  78. 8.13.5 Biogen Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Drugs for the Treatment of Refractory Gout Product Portfolio
  84. 8.14.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for the Treatment of Refractory Gout Value Chain Analysis
  2. 9.1.1 Drugs for the Treatment of Refractory Gout Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for the Treatment of Refractory Gout Production Mode & Process
  6. 9.2 Drugs for the Treatment of Refractory Gout Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for the Treatment of Refractory Gout Distributors
  9. 9.2.3 Drugs for the Treatment of Refractory Gout Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst